1st Quarter - Report — TERUMO BCT, INC. for TERUMO BCT, INC. (2024)

Firm

TERUMO BCT, INC.

Client

TERUMO BCT, INC.

Income

—

Expenses

$120,000

Expense method

A: Lobbying Disclosure Act definitions

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

-Access to Therapeutic Apheresis, generally. -Sickle Cell Disease issues, generally; S.1852, Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023. -Blood collection issues, generally. -Medical device sterilization. -ARPA-H, cell collections issues, generally.

Lobbyist	Covered position, as disclosed
ANDREA HECHAVARRIA	—

Contacted: SENATE; White House Office; Office of Management & Budget (OMB); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Environmental Protection Agency (EPA)

Bills named: S. 1852 (118th)

Medicare/Medicaid MMM

-Access to Therapeutic Apheresis, generally. -Issues related to CY 2024 Physician Fee Schedule. -Issues related to CY 2024 OPPS Proposed Rule. -Sickle Cell Disease issues, generally.

Lobbyist	Covered position, as disclosed
ANDREA HECHAVARRIA	—

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS)

Trade (domestic/foreign) TRD

-Export license applications.

Lobbyist	Covered position, as disclosed
ANDREA HECHAVARRIA	—

Contacted: Bureau of Industry and Security (BIS)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.